The alternative text for this image may have been generated using AI. Figure 2: Regulation of the TGFBR2 promoter by EWS-FLI1 and FLI1, and electrophoretic mobility shift assay of in vitro-translated ...
This study highlights the potential for using deep learning methods on longitudinal health data from both primary and secondary care to develop low-cost predictive tools for screening of young-onset ...
Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or ...
Most patients with new-onset type 1 diabetes have substantial intact beta-cell reserve. 1 Thus, we analyzed the efficacy of semaglutide, an agonist of glucagon-like peptide 1 (GLP-1), in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results